{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:53:10Z","timestamp":1762005190732,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ijantimicag.2020.106045","type":"journal-article","created":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T18:25:06Z","timestamp":1591467906000},"page":"106045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015\u20132017"],"prefix":"10.1016","volume":"56","author":[{"given":"Gregory G","family":"Stone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl Erik","family":"Nord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106045_bib0001","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13054-015-0926-5","article-title":"An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumoniae: impact of multidrug resistance","volume":"19","author":"Micek","year":"2015","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2020.106045_bib0002","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.diagmicrobio.2012.11.009","article-title":"Carbapenemase-resistant Enterobacteriaceae: a review of treatment and outcomes","volume":"75","author":"van Duin","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"volume":"2017","year":"2017","key":"10.1016\/j.ijantimicag.2020.106045_bib0003"},{"key":"10.1016\/j.ijantimicag.2020.106045_bib0004","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12879-017-2383-z","article-title":"Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary infection, pneumonia and sepsis","volume":"17","author":"Zilderberg","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106045_bib0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.ijantimicag.2020.106045_bib0006","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01076-18","article-title":"Past and present perspectives on \u03b2-lactamases","volume":"62","author":"Bush","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106045_bib0007","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","article-title":"The global epidemiology of carbapenemase-producing Enterobacteriaceae","volume":"8","author":"van Duin","year":"2017","journal-title":"Virulence"},{"key":"10.1016\/j.ijantimicag.2020.106045_bib0008","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2020.106045_bib0009","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1128\/AAC.00574-09","article-title":"Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa","volume":"53","author":"Rodriguez-Martinez","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106045_bib0010","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1128\/AAC.00257-10","article-title":"Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to \u03b2-lactam antibiotics","volume":"54","author":"Alvarez-Ortega","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106045_bib0011","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1128\/AAC.01388-12","article-title":"Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones","volume":"56","author":"Cabot","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106045_bib0012","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1186\/1471-2334-13-505","article-title":"Carbapenemase-producing Pseudomonas aeruginosa from central Greece: molecular epidemiology and genetic analysis of class I integrons","volume":"13","author":"Liakopoulos","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106045_bib0013","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1128\/AAC.03042-15","article-title":"In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study","volume":"60","author":"de Jonge","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106045_sbref0014","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dky266","article-title":"In vitro activity of ceftazidime-avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012-2015","author":"Kazmierczak","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106045_sbref0015","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dky267","article-title":"In vitro activity of ceftazidime-avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012\u20132015","author":"Kazmierczak","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106045_bib0016","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1128\/AAC.03057-14","article-title":"Avibactam and class C \u03b2-lactamases: mechanisms of inhibition, conservation of the binding pocket, and implications for resistance","volume":"58","author":"Lahiri","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106045_bib0017","unstructured":"Pfizer Pharmaceuticals. Zavicefta Summary of Product Characteristics. Available at:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004027\/WC500210234.pdf. [Accessed 08 May 2019]"},{"year":"2015","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards","key":"10.1016\/j.ijantimicag.2020.106045_bib0018"},{"key":"10.1016\/j.ijantimicag.2020.106045_bib0019","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 2019. Available at:http:\/\/www.eucast.org. [Accessed 07 May 2019]"},{"key":"10.1016\/j.ijantimicag.2020.106045_bib0020","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"81","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"year":"2016","series-title":"Performance standards for antimicrobial susceptibility testing: Twenty-sixth informational supplement M100-S26","key":"10.1016\/j.ijantimicag.2020.106045_bib0021"},{"key":"10.1016\/j.ijantimicag.2020.106045_bib0022","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1128\/AAC.05186-14","article-title":"Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART Program, 2009 to 2013","volume":"59","author":"Lob","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.ijantimicag.2020.106045_bib0023","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1128\/AAC.00220-16","article-title":"In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014)","volume":"60","author":"Nichols","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.ijantimicag.2020.106045_bib0024","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/jac\/dky107","article-title":"In vitro activity of imipenem\/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme","volume":"73","author":"Karlowsky","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106045_bib0025","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jac\/dkx009","article-title":"Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance program","volume":"72","author":"Pfaller","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106045_bib0026","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00514-19","article-title":"In vitro activity of cefepime-enmetazobactam against Gram-negative isolates collected from United States and European hospitals during 2014\u20132015","author":"Morrissey","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"year":"2018","series-title":"Surveillance of antimicrobial resistance in Europe \u2013 Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2017","key":"10.1016\/j.ijantimicag.2020.106045_bib0027"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920302156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920302156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:38:38Z","timestamp":1760377118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920302156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0924857920302156"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106045","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015\u20132017","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106045"}}